Travere Therapeutics (TVTX) Other Accumulated Expenses (2014 - 2026)

Travere Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Other Accumulated Expenses fell 86.67% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 86.67% YoY) and the FY2025 annual result came in at $3.2 million, down 81.33% from the prior year.
• Other Accumulated Expenses was $2.1 million for Q1 2026 at Travere Therapeutics, down from $3.2 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $17.1 million in Q4 2024 and bottomed at $2.1 million in Q1 2026.
• A 5-year average of $7.0 million and a median of $5.4 million in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses jumped 226.64% — and 2026, when it sank 86.67%.
• Travere Therapeutics' Other Accumulated Expenses stood at $5.7 million in 2022, then slipped by 8.48% to $5.2 million in 2023, then soared by 226.64% to $17.1 million in 2024, then plunged by 81.33% to $3.2 million in 2025, then slumped by 34.25% to $2.1 million in 2026.
• Business Quant data shows TVTX's Other Accumulated Expenses at $2.1 million in Q1 2026, $3.2 million in Q4 2025, and $5.4 million in Q3 2025.